MiRNA-200c-3p is crucial in acute respiratory distress syndrome

Cell Discovery

Volumn 3, Issue , 2017, Pages

  Liu, Qiang ^a   Du, Jianchao ^a   Yu, Xuezhong ^b   Xu, Jun ^b   Huang, Fengming ^a   Li, Xiaoyun ^a   Zhang, Cong ^c   Li, Xiao ^d   Chang, Jiahui ^a   Shang, Daozhen ^a   Zhao, Yan ^a   Tian, Mingyao ^d   Lu, Huijun ^d   Xu, Jiantao ^a   Li, Chang ^d   Zhu, Huadong ^b   Jin, Ningyi ^d   Jiang, Chengyu ^a,e  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^d BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^e SICHUAN UNIVERSITY   (China)

Author keywords

Angiotensin; influenza; LPS; LTA; miRNA; Pneumonia; Poly (I:C)

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; BACTERIUM LIPOPOLYSACCHARIDE; DOUBLE STRANDED RNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOTEICHOIC ACID; MICRORNA; MICRORNA 200C 3P; NONSTRUCTURAL PROTEIN 1; UNCLASSIFIED DRUG; VIRUS RNA;

3' UNTRANSLATED REGION; A-549 CELL LINE; ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLUENZA A (H5N1); INFLUENZA A VIRUS (H5N1); MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; UPREGULATION; VIRUS REPLICATION;

EID: 85021416731     PISSN: None     EISSN: 20565968     Source Type: Journal    
DOI: 10.1038/celldisc.2017.21     Document Type: Article

References (72)

1. Short KR, Kroeze EJBV, Fouchier RAM, Kuiken T. Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect Dis 2014; 14: 57-69.
2. Herold S, Becker C, Ridge KM, Budinger GR. Influenza virus-induced lung injury: Pathogenesis and implications for treatment. Eur Respir J 2015; 45: 1463-1478.
3. McCullers JA. The co-pathogenesis of influenza viruses with bacteria in the lung. Nat Rev Microbiol 2014; 12: 252-262.
4. Barik S. New treatments for influenza. BMC Med 2012; 10: 104.
5. Jacob A, Sood R, Chanu KhV, et al. Amantadine resistance among highly pathogenic avian influenza viruses (H5N1) isolated from India. Microb Pathog 2016; 91: 35-40.
6. Maurer-Stroh S, Li Y, Bastien N, et al. Potential human adaptation mutation of influenza A(H5N1) virus, Canada. Emerg Infect Dis 2014; 20: 1580-1582.
7. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-E9.
8. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captoprilinsensitive carboxypeptidase. J Biol Chem 2000; 275: 33238-33243.
9. Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002; 277: 14838-14843.
10. Michel MC, Brunner HR, Foster C, Huo Y. Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease. Pharmacol Ther 2016; 164: 1-81.
11. Chow BS, Allen TJ. Angiotensin II type 2 receptor (AT2R) in renal and cardiovascular disease. Clin Sci 2016; 130: 1307-1326.
12. Patel VB, Zhong JC, Grant MB, Oudit GY. Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ Res 2016; 118: 1313-1326.
13. Crackower MA, Sarao R, Oudit GY, et al. Angiotensinconverting enzyme 2 is an essential regulator of heart function. Nature 2002; 417: 822-828.
14. Burrell LM, Burchill L, Dean RG, Griggs K, Patel SK, Velkoska E. Chronic kidney disease: Cardiac and renal angiotensin-converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition. Exp Physiol 2012; 97: 477-485.
15. Hashimoto T, Perlot T, Rehman A, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature 2012; 487: 477-481.
16. Zou Z, Yan Y, Shu Y, et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat Commun 2014; 5: 3594.
17. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005; 11: 875-879.
18. Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005; 436: 112-116.
19. Yan Y, Liu Q, Li N, et al. Angiotensin II receptor blocker as a novel therapy in acute lung injury induced by avian influenza A H5N1 virus infection in mouse. Sci China Life Sci 2015; 58: 208-211.
20. Gu H, Xie Z, Li T, et al. Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus. Scientific Rep 2016; 6: 19840.
21. Huang F, Guo J, Zou Z, et al. Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients. Nat Commun 2014; 5: 3595.
22. Kuba K, Imai Y, Penninger JM. Angiotensin-converting enzyme 2 in lung diseases. Curr Opin Pharmacol 2006; 6: 271-276.
23. Li Y, Zeng Z, Cao Y, et al. Angiotensin-converting enzyme 2 prevents lipopolysaccharide-induced rat acute lung injury via suppressing the ERK1/2 and NF-kappaB signaling pathways. Scientific Rep 2016; 6: 27911.
24. Wang K, Liu X, Xiao H, Wang H, Zhang Y. The correlation between inflammatory injury induced by LPS and RAS in EpH4-Ev cells. Int Immunopharmacol 2017; 46: 23-30.
25. Tao L, Qiu Y, Fu X, et al. Angiotensin-converting enzyme 2 activator diminazene aceturate prevents lipopolysaccharide-induced inflammation by inhibiting MAPK and NF-kappaB pathways in human retinal pigment epithelium. J Neuroinflamm 2016; 13: 35.
26. He L, Hannon GJ. MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5: 522-531.
27. Christopher AF, Kaur RP, Kaur G, Kaur A, Gupta V, Bansal P. MicroRNA therapeutics: Discovering novel targets and developing specific therapy. Perspect Clin Res 2016; 7: 68-74.
28. Schmidt MF. Drug target miRNAs: Chances and challenges. Trends Biotechnol 2014; 32: 578-585.
29. Mutlu M, Raza U, Saatci O, Eyupoglu E, Yurdusev E, Sahin O. miR-200c: A versatile watchdog in cancer progression, EMT, drug resistance. J Mol Med 2016; 94: 629-644.
30. Filios SR, Xu G, Chen J, Hong K, Jing G, Shalev A. MicroRNA-200 is induced by thioredoxin-interacting protein and regulates Zeb1 protein signaling and beta cell apoptosis. J Biol Chem 2014; 289: 36275-36283.
31. Lambert DW, Lambert LA, Clarke NE, Hooper NM, Porter KE, Turner AJ. Angiotensin-converting enzyme 2 is subject to post-transcriptional regulation by miR-421. Clin Sci 2014; 127: 243-249.
32. Lam WY, Yeung AC, Ngai KL, et al. Effect of avian influenza A H5N1 infection on the expression of microRNA-141 in human respiratory epithelial cells. BMC Microbiol 2013; 13: 104.
33. Gupta A, Rhodes GJ, Berg DT, Gerlitz B, Molitoris BA, Grinnell BW. Activated protein C ameliorates LPS-induced acute kidney injury and downregulates renal INOS and angiotensin 2. Am J Physiol Renal Physiol 2007; 293: F245-F254.
34. He H, Liu L, Chen Q, et al. Mesenchymal stem cells overexpressing angiotensin-converting enzyme 2 rescue lipopolysaccharide-induced lung injury. Cell Transplant 2015; 24: 1699-1715.
35. Lee KH, Gordon A, Foxman B. The role of respiratory viruses in the etiology of bacterial pneumonia: An ecological perspective. Evol Med Public Health 2016; 2016: 95-109.
36. Bauer TT, Ewig S, Rodloff AC, Muller EE. Acute respiratory distress syndrome and pneumonia: A comprehensive review of clinical data. Clin Infect Dis 2006; 43: 748-756.
37. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med 2005; 353: 1685-1693.
38. Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 2016; 315: 788-800.
39. Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: The Berlin definition. JAMA 2012; 307: 2526-2533.
40. Wenz M, Hoffmann B, Bohlender J, Kaczmarczyk G. Angiotensin II formation and endothelin clearance in ARDS patients in supine and prone positions. Intens Care Med 2000; 26: 292-298.
41. Rahman MM, McFadden G. Modulation of NF-kappaB signalling by microbial pathogens. Nat Rev Microbiol 2011; 9: 291-306.
42. Hayden MS, Ghosh S. NF-kappaB in immunobiology. Cell Res 2011; 21: 223-244.
43. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006; 103: 12481-12486.
44. Zhou R, Hu G, Liu J, Gong AY, Drescher KM, Chen XM. NF-kappaB p65-dependent transactivation of miRNA genes following Cryptosporidium parvum infection stimulates epithelial cell immune responses. PLoS Pathogens 2009; 5: E1000681.
45. Niu J, Shi Y, Tan G, et al. DNA damage induces NF-kappaB-dependent microRNA-21 up-regulation and promotes breast cancer cell invasion. J Biol Chem 2012; 287: 21783-21795.
46. Imai Y, Kuba K, NeelyGGet al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 2008; 133: 235-249.
47. Schmolke M, Viemann D, Roth J, Ludwig S. Essential impact of NF-kappaB signaling on the H5N1 influenza A virus-induced transcriptome. J Immunol 2009; 183: 5180-5189.
48. Kumar N, Xin ZT, Liang Y, Ly H, Liang Y. NF-kappaB signaling differentially regulates influenza virus RNA synthesis. J Virol 2008; 82: 9880-9889.
49. Wang X, Li M, Zheng H, et al. Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha/beta interferon. J Virol 2000; 74: 11566-11573.
50. Visvanathan KV, Goodbourn S. Double-stranded RNA activates binding of NF-kappa B to an inducible element in the human beta-interferon promoter. EMBO J 1989; 8: 1129-1138.
51. Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 1986; 47: 921-928.
52. Busam K, Gieringer C, Freudenberg M, Hohmann HP. Staphylococcus aureus and derived exotoxins induce nuclear factor kappa B-like activity in murine bone marrow macrophages. Infect Immun 1992; 60: 2008-2015.
53. Xu T, Qiao J, Zhao L, et al. Acute respiratory distress syndrome induced by avian influenza A (H5N1) virus in mice. Am J Respir Crit Care Med 2006; 174: 1011-1017.
54. Matute-Bello G, Downey G, Moore BB, et al. An official American Thoracic Society workshop report: Features and measurements of experimental acute lung injury in animals. Am J Respir Cell Mol Biol 2011; 44: 725-738.
55. Yu H, Gao Z, Feng Z, et al. Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in China. PLoS ONE 2008; 3: E2985.
56. Beigel JH, Farrar J, Han AM, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353: 1374-1385.
57. Marazzi I, Ho JS, Kim J, et al. Suppression of the antiviral response by an influenza histone mimic. Nature 2012; 483: 428-433.
58. Marc D. Influenza virus non-structural protein NS1: Interferon antagonism and beyond. J Gen Virol 2014; 95: 2594-2611.
59. Kainov DE, Muller KH, Theisen LL, Anastasina M, Kaloinen M, Muller CP. Differential effects of NS1 proteins of human pandemic H1N1/2009, avian highly pathogenic H5N1, low pathogenic H5N2 influenza A viruses on cellular pre-mRNA polyadenylation and mRNA translation. J Biol Chem 2011; 286: 7239-7247.
60. Batista L, Bourachot B, Mateescu B, Reyal F, Mechta-Grigoriou F. Regulation of miR-200c/141 expression by intergenic DNA-looping and transcriptional readthrough. Nat Commun 2016; 7: 8959.
61. Liu X, Yang N, Tang J, et al. Downregulation of angiotensin-converting enzyme 2 by the neuraminidase protein of influenza A (H1N1) virus. Virus Res 2014; 185: 64-71.
62. Flory E, Kunz M, Scheller C, et al. Influenza virus-induced NF-kappaB-dependent gene expression is mediated by overexpression of viral proteins and involves oxidative radicals and activation of IkappaB kinase. J Biol Chem 2000; 275: 8307-8314.
63. Zhang Y, Tang J, Yang N, et al. FAT10 is critical in influenza A virus replication by inhibiting type I IFN. J Immunol 2016; 197: 824-833.
64. Ladeiro Y, Couchy G, Balabaud C, et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology (Baltimore, MD) 2008; 47: 1955-1963.
65. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413: 732-738.
66. Takeuchi O, Hoshino K, Kawai T, et al. Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity 1999; 11: 443-451.
67. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002; 2: 725-734.
68. Ohkubo T, Chapman N, Neal B, et al. Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Am J Respir Crit Care Med 2004; 169: 1041-1045.
69. Mortensen EM, Nakashima B, Cornell J, et al. Populationbased study of statins, angiotensin II receptor blockers, angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis 2012; 55: 1466-1473.
70. Jiang Z, Tao JH, Zuo T, et al. The correlation between miR-200c and the severity of interstitial lung disease associated with different connective tissue diseases. Scand J Rheumatol 2016; 46: 122-129.
71. Xiao J, Tang J, Chen Q, et al. miR-429 regulates alveolar macrophage inflammatory cytokine production and is involved in LPS-induced acute lung injury. Biochem J 2015; 471: 281-291.
72. Ju X, Yan Y, Liu Q, et al. Neuraminidase of influenza A virus binds lysosome-associated membrane proteins directly and induces lysosome rupture. J Virol 2015; 89: 10347-10358.